Company Financials
Fusion Antibodies plc Financials
Pound sterling
business
Fusion Antibodies plc Company Profile
Main Stock Listing
LSE: FAB
Market Capitalization £7.3 Million as of July 1, 2025
Market Cap History
Valuations Metrics as of May. 5, 2024
| Trailing PE | -33.50 |
| Forward PE | -1.34 |
| Price to Sales TTM | £2.05 |
| Price to Book MRQ | £139.58 |
| Enterprise to Revenue | 0.98 |
| Enterprise to EBITDA | -0.55 |
Financial Reports as of Sep. 30, 2023
Financials
| Fiscal Year Ends | 2023-03-31 |
| Most Recent Quarter | 2023-09-30 |
| Profit Margin | -179.67% |
| Operating Margin | -262.29% |
| Return on Assets TTM | -62.52% |
| Return on Equity TTM | -140.93% |
Income Statement
| Revenue TTM | £1,579,000 |
| Revenue per Share TTM | £0.04 |
| Quarterly Revenue Growth | -71.00% |
| Gross Profit TTM | £574,000 |
| EBITDA | £-2,799,000 |
| Net Income to Common TTM | £-2,837,000 |
| Diluted EPS TTM | £-0.09 |
| Quarterly Earnings Growth YoY | % |
Balance Sheet
| Total Cash MRQ | £487,000 |
| Total Cash per Share MRQ | £0.01 |
| Total Debt MRQ | £ |
| Total Debt to Equity MRQ | 3.23 |
| Current Ratio MRQ | 3.26 |
| Book Value per Share MRQ | £0.02 |
Cash Flow
| Operating Cash Flow TTM | £-2,351,000 |
| Levered Free Cash Flow TTM | £-1,148,125 |
FAB Stock Info as of May. 5, 2024
Stock Statistics
| Shares Outstanding | 95,365,600 |
| Float Shares | 55,989,346 |
| Avg 10 Volume | 737,936 |
| Avg 30 Volume | None |
| Shares Short | None |
| Short Ratio | |
| Short % of Shares | % |
| % Held by Insiders | 10.37% |
| % Held by Institutions | 24.43% |
Stock Price Summary
| Beta | 0.44 |
| Fifty Two Week Low | £3.02 |
| Fifty Two Week High | £41.80 |
| Fifty Two Week Change | -1094.03% |
| Day 50 MA | £3.83 |
| Day 200 MA | £4.86 |
Dividends and Splits
| Forward Annual Dividend Rate | £ |
| Forward Annual Dividend Yield | % |
| Trailing Annual Dividend Rate | £0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Payout Ratio | 0.00% |
| Dividend Date | |
| Ex Dividend Date | |
| Last Split Factor | |
| Last Split Date |